Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Year: 2025
Type: erratum
Abstract: Following publication of the original article [1], Figure 1A contained incorrect blots.Specifically, the blots for pEGFR, EGFR, pMAPK, MAPK, and α-tubulin were inadvertently sourced from a previous publication.After working closely with the editorial team, the authors have now provided the correct blots for Figure 1A.This correction does not impact the findings or conclusions of the article.The authors sincerely regret any inconvenience this may have caused and appreciate the opportunity to make this correction.The correct Fig. 1 is shown below.
Source: Molecular Cancer
Institutions: University of Wisconsin–Madison, University of Chicago
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,090
OpenAlex ID: W7117531234